- Izotropic recently published a piece that explores the way AI is redefining breast imaging and the way the innovative IzoView system was designed for the future
- The company’s 3D breast CT platform helps tackle one of the major concerns of cancer screening: radiation exposure in CT imaging
- With its trade-secret reconstruction algorithm, AI-native design, and fair price model, IzoView strategically places Izotropic to dominate the future of breast imaging technology
- These latest updates further highlight Izotropic’s mission: to redefine breast diagnostics using innovation that prioritizes safety, precision, and accessibility
Izotropic (CSE: IZO) (OTCQB: IZOZF) is changing how breast cancer imaging is done using its IzoView system, a CT platform designed for AI integration. Recent studies from the NIH show that there are increasing concerns about the radiation coming from CT scans. Izotropic’s technology presents a solution that helps optimize breast images while prioritizing dose risk (ibn.fm/NqSvV).
The company’s latest piece highlights how AI is changing the game for cancer detection. Studies conducted in the U.S. and Europe show that AI-assisted mammography boosts overall accuracy by about 18% while optimizing diagnostic workflows. However, many AI tools operate on old hardware, not designed for the heavy demands of AI and the challenges that come with imaging breast tissue. The IzoView innovation bridges this gap.
IzoView uses a unique machine-learning algorithm that works on raw X-ray information into de-noise it outputs images without the need to increase radiation dose. This technology is a product of studies in collaboration with the Johns Hopkins University School of Medicine and leverages 15 years’ worth of specialized breast CT images, that offer ~100x greater spatial resolution than MRI. The blend of safety and performance helps solve one of the biggest challenges in cancer screening: maintaining low radiation exposure without compromising on image quality.
According to recent estimates by the NIH, current CT imaging practices in America could lead to over 100,000 future cancer occurrences if scan frequency and dose levels don’t change. The company’s strategy addresses this fear by redefining the CT imaging framework on AI efficiency, leading to high-fidelity, low-dose imaging that could boost diagnostic confidence while prioritizing patient safety.
Izotropic has plans to expand the IzoView imaging platform. The company holds the only U.S. patent for AI-based computer-aided diagnosis in breast CT, an important feature that could enable radiologists to triage caseloads and identify abnormalities quickly and efficiently (ibn.fm/BC2KQ). IzoView’s target price of half a million dollars means that it would cost three times less than the competition, thereby boosting access for imaging centers and hospitals globally.
With these latest updates, Izotropic’s mission to deliver AI-driven medical imaging that protects patients and empowers clinicians is further highlighted. With the increased adoption of AI in the healthcare industry, IzoView holds a strategic position as an economic and clinical differentiator. Its strategy is to detect cancer early enough in an intelligent, safe, and efficient manner.
For more information, visit the company’s website at www.IzoCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
